Karyopharm Therapeutics Inc. (KPTI) vs Sangamo Therapeutics, Inc. (SGMOQ)
Karyopharm Therapeutics Inc. and Sangamo Therapeutics, Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and Sangamo Therapeutics, Inc. are of similar size ($41.9M and $39.2M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −45.8%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −356.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Karyopharm Therapeutics Inc. leads on 11 and Sangamo Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | KPTI | SGMOQ | Biotechnology median |
|---|---|---|---|
| Gross margin | 95.89% | 100.00% | 65.16% |
| Operating margin | (56.17%) | (357.55%) | 0.00% |
| Net margin | (153.28%) | (356.89%) | 0.00% |
| Free cash flow margin | (44.57%) | (261.76%) | 0.00% |
| Return on equity | 78.98% | 1,755.72% | (57.72%) |
| Return on assets | (207.90%) | (168.79%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack